4-苯基哒嗪-3,6-二酮 | 453511-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-苯基哒嗪-3,6-二酮
• 英文名称: 4-phenylpyridazin-3,6-dione
• 英文别名: 4-Phenylpyridazine-3,6-dione；4-phenyl-3,6-pyridazinedione
• CAS: 453511-76-7
• 化学式: C₁₀H₆N₂O₂
• 分子量: 186.17
• InChiKey: KFJCVCYLUVIDFY-UHFFFAOYSA-N

物化性质

• 沸点：
  337.7±45.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苯基哒嗪-3,6-二酮 在 一水合肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 32.0h， 生成 6-chloro-5-phenyl-3-pyridazinylhydrazine
  参考文献：
  名称：

  7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine:  A Functionally Selective γ-Aminobutyric Acid_A (GABA_A) α2/α3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models

  摘要：

  There is increasing evidence that compounds with selectivity for gamma-aminobutyric acid(A) (GABA(A)) alpha 2- and/or alpha 3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect profile. Herein we describe a novel series of GABA(A) alpha 2/alpha 3 subtype-selective agonists leading to the identification of the development candidate 17, a nonsedating anxiolytic in preclinical animal assays.

  DOI：

  10.1021/jm058034a
• 作为产物：
  描述：

  苯基顺酐 在 sodium acetate trihydrate 、 一水合肼 、 溶剂黄146 作用下， 生成 4-苯基哒嗪-3,6-二酮
  参考文献：
  名称：

  Triazolopyridazine derivatives for treating anxiety and enhancing cognition

  摘要：

  一种具有化学式I的化合物，或其盐或前药：其中：Z代表C1-6烷基，C3-7环烷基，C4-7环烯基，芳基，C3-7杂环烷基，杂芳基或二(C1-6)烷基氨基，其中任何这些基团均可选择性地被取代；R1代表选择自噁唑，噻唑，异噁唑，异硫唑，咪唑，吡唑，噁二唑，噻二唑，三唑和四唑中的一种选择性地取代的五元杂芳环；或R1代表选择自吡啶，嘧啶和吡啶并[1,2-a]吡嗪中的一种选择性地取代的六元杂芳环；以及R2代表氰基(C1-6)烷基，羟基(C1-6)烷基，C3-7环烷基(C1-6)烷基，丙炔基，C3-7杂环烷基羰基(C1-6)烷基，芳基(C1-6)烷基或杂芳基(C1-6)烷基，其中任何这些基团均可选择性地被取代；其用于治疗焦虑和包含它的制药组合物；还公开了一类在增强认知方面有用的化合物，例如阿尔茨海默病。

  公开号：

  US06297235B1

文献信息

• [EN] DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIDAZINES 6-SUBSTITUÉES EN TANT QU'AGONISTES DE REV-ERB
  申请人：GENFIT

  公开号：WO2013045519A1

  公开（公告）日：2013-04-04

  The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

  本发明提供了新颖的激动Rev-Erb的6-取代[1,2,4]三唑并[4,3-b]吡啶嗪化合物。这些化合物以及包含它们的药物组合物是治疗任何激活Rev-Erb具有治疗效果的疾病的合适手段，例如在炎症和昼夜节律相关疾病或心脏代谢疾病中。
• Triazolopyridazine derivatives for treating anxiety and enhancing cognition
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06297235B1

  公开（公告）日：2001-10-02

  A compound of formula I, or a salt or prodrug thereof: wherein: Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, aryl, C3-7 heterocycloalkyl, heteroaryl or di(C1-6)alkylamino, any of which groups may be optionally substituted; R1 represents an optionally substituted five-membered heteroaromatic ring selected from oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or R1 represents an optionally substituted six-membered heteroaromatic ring selected from pyrazine, pyrimidine and pyridazine; and R2 represents cyano(C1-6)alkyl, hydroxy(C1-6)alkyl, C3-7 cycloalkyl(C1-6)alky, propargyl, C3-7 heterocycloalkylcarbonyl(C1-6)alkyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; its use in treating anxiety and pharmaceutical compositions comprising it; a subclass of compounds which are useful in enhancing cognition, such as Alzheimer's Disease, is also disclosed.

  一种具有化学式I的化合物，或其盐或前药：其中：Z代表C1-6烷基，C3-7环烷基，C4-7环烯基，芳基，C3-7杂环烷基，杂芳基或二(C1-6)烷基氨基，其中任何这些基团均可选择性地被取代；R1代表选择自噁唑，噻唑，异噁唑，异硫唑，咪唑，吡唑，噁二唑，噻二唑，三唑和四唑中的一种选择性地取代的五元杂芳环；或R1代表选择自吡啶，嘧啶和吡啶并[1,2-a]吡嗪中的一种选择性地取代的六元杂芳环；以及R2代表氰基(C1-6)烷基，羟基(C1-6)烷基，C3-7环烷基(C1-6)烷基，丙炔基，C3-7杂环烷基羰基(C1-6)烷基，芳基(C1-6)烷基或杂芳基(C1-6)烷基，其中任何这些基团均可选择性地被取代；其用于治疗焦虑和包含它的制药组合物；还公开了一类在增强认知方面有用的化合物，例如阿尔茨海默病。
• Triazolopyridazine Derivatives for treating anxiety and enhancing cognition
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06444666B1

  公开（公告）日：2002-09-03

  A compound of formula I, or a salt or prodrug thereof: wherein: Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, aryl, C3-7 heterocycloalkyl, heteroaryl or di(C1-6)alkylamino, any of which groups may be optionally substituted; R1 represents an optionally substituted five-membered heteroaromatic ring selected from oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or R1 represents an optionally substituted six-membered heteroaromatic ring selected from pyrazine, pyrimidine and pyridazine; and R2 represents cyano(C1-6)alkyl, hydroxy(C1-6)alkyl, C3-7 cycloalkyl(C1-6)alkyl, propargyl, C3-7 heterocycloalkylcarbonyl(C1-6)alkyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; its use in treating anxiety and pharmaceutical compositions comprising it; a subclass of compounds which are useful in enhancing cognition, such as Alzheimer's Disease, is also disclosed.

  式I的化合物，或其盐或前药：其中：Z代表C1-6烷基，C3-7环烷基，C4-7环烯基，芳基，C3-7杂环烷基，杂芳基或双（C1-6）烷基氨基，其中任何一个基团均可选择性地被取代；R1代表可选择性取代的五元杂芳香环，所选的环包括噁唑，噻唑，异噁唑，异硫唑，咪唑，吡唑，噻二唑，噻二唑，三唑和四唑；或R1代表可选择性取代的六元杂芳香环，所选的环包括吡嗪，嘧啶和吡嗪啉；且R2代表氰基（C1-6）烷基，羟基（C1-6）烷基，C3-7环烷基（C1-6）烷基，丙炔基，C3-7杂环烷基羰基（C1-6）烷基，芳基（C1-6）烷基或杂芳基（C1-6）烷基，其中任何一个基团均可选择性地被取代；其在治疗焦虑症方面的用途及包含该化合物的制药组合物；还公开了一类有益于增强认知能力的化合物，如阿尔茨海默病。
• DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
  申请人：GENFIT

  公开号：US20150038503A1

  公开（公告）日：2015-02-05

  The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

  本发明提供了新型的6-取代[1,2,4]三唑并[4,3-b]吡啶嗪，这些化合物是Rev-Erb激动剂。这些化合物及其含有的药物组合物是治疗任何需要Rev-Erb激活具有治疗效果的疾病的适当手段，例如炎症和昼夜节律相关疾病或心脏代谢疾病。
• (3,6-Pyridazinediylbis(thio))bis-(2,2-dimethylalkanoic acids) and derivatives thereof, suitable as anti-arteriosclerotic agents, processes for the production of such compounds and pharmaceutical compositions including such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0084720A1

  公开（公告）日：1983-08-03

  New substituted [3,6-pyridazinediylbis(thio)] bis-[2,2-dimethylalkanoic acids] and derivatives which are useful as anti-arteriosclerotic agents are disclosed. These compounds elevate the high density lipoprotein fraction of cholesterol, and also lower the low density lipoprotein fraction of cholesterol. The compounds have the following formula: wherein each of m and n, which are the same or different, is an integer from 3 to 6; X is a hydrogen atom, a phenyl radical or an alkyl radical of from 1 to 6 carbon atoms; each of R' and R2, which are the same or different is a hydrogen atom, an alkyl radical of from 1 to 6 carbon atoms, or a pharmaceutically acceptable cation.

  本发明公开了可用作抗动脉硬化药物的新型取代[3,6-哒嗪二基双（硫）]双-[2,2-二甲基烷酸]及其衍生物。 这些化合物可提高胆固醇的高密度脂蛋白分数，也可降低胆固醇的低密度脂蛋白分数。 这些化合物具有下式：其中相同或不同的 m 和 n 均为 3 至 6 的整数；X 为氢原子、苯基或 1 至 6 个碳原子的烷基；相同或不同的 R' 和 R2 均为氢原子、1 至 6 个碳原子的烷基或药学上可接受的阳离子。